GDC-0829

GDC-0829 is an experimental small molecule drug being developed by Genentech (a member of the Roche Group) for the treatment of infectious diseases. As of 2024, it is in Phase I clinical development, with studies focusing on its safety, tolerability, and pharmacokinetics in healthy volunteers following intravenous administration. While the specific biological target and mechanism of action have not been publicly disclosed, the "GDC" designation typically indicates a small molecule candidate discovered or developed by Genentech. The drug is being evaluated in both single ascending dose (SAD) and multiple ascending dose (MAD) cohorts to establish its profile for potential use against bacterial or viral infections.